Clinical Trials
25 trialsNCT07209111 2026-05-26
KANDLELIT-014
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07252739 2026-05-26
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05271604 2025-09-26
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc.
Phase 2 Completed
NCT06978400 2025-05-18
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
Phase 2 Recruiting
NCT06575127 2024-08-28
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Al-Azhar University
Phase 2 Recruiting
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT00598975 2021-07-12
NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
Nektar Therapeutics
Phase 2 Completed
NCT00957853 2020-03-19
Preoperative Treatment With Cetuximab and/or IMC-A12
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02123381 2020-03-17
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT00468169 2019-10-09
EPIC
University of Chicago
Phase 2 Completed
NCT00845039 2018-07-02
FC-4
Eli Lilly and Company
Phase 2 Terminated
NCT00870870 2018-06-01
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Eli Lilly and Company
Phase 2 Completed
NCT01524978 2017-11-20
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Hoffmann-La Roche
Phase 2 Completed
NCT02316496 2017-08-01
REGAIN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00226239 2017-07-11
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT00703976 2017-04-04
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00350025 2017-03-31
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00996567 2017-02-09
MesoMab
University Hospital, Ghent
Phase 2 Completed
NCT00439517 2014-06-27
FUTURE
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00463788 2014-02-13
BALI-1
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00795301 2014-01-14
A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab
National University Hospital, Singapore
Phase 2 Unknown
NCT00297128 2011-12-30
Preoperative Chemoradiation With Capecitabine and Cetuximab
Austrian Breast & Colorectal Cancer Study Group
Phase 2 Completed
NCT00083720 2011-05-25
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT00063388 2010-04-12
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed